Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Total Debt (2020 - 2022)

Historic Total Debt for RedHill Biopharma (RDHL) over the last 3 years, with Q4 2022 value amounting to $230.4 million.

  • RedHill Biopharma's Total Debt rose 17557.04% to $230.4 million in Q4 2022 from the same period last year, while for Dec 2022 it was $230.4 million, marking a year-over-year increase of 17557.04%. This contributed to the annual value of $230.4 million for FY2022, which is 17557.04% up from last year.
  • According to the latest figures from Q4 2022, RedHill Biopharma's Total Debt is $230.4 million, which was up 17557.04% from $113.9 million recorded in Q3 2022.
  • In the past 5 years, RedHill Biopharma's Total Debt registered a high of $230.4 million during Q4 2022, and its lowest value of $78.2 million during Q1 2020.
  • Moreover, its 3-year median value for Total Debt was $83.3 million (2021), whereas its average is $97.3 million.
  • Per our database at Business Quant, RedHill Biopharma's Total Debt skyrocketed by 274.49% in 2021 and then soared by 17557.04% in 2022.
  • RedHill Biopharma's Total Debt (Quarter) stood at $81.4 million in 2020, then grew by 2.74% to $83.6 million in 2021, then skyrocketed by 175.57% to $230.4 million in 2022.
  • Its Total Debt stands at $230.4 million for Q4 2022, versus $113.9 million for Q3 2022 and $85.5 million for Q2 2022.